Exicure (XCUR) Revenue (2016 - 2024)

Exicure's (XCUR) quarterly Revenue came in at $500000.0 in Q1 2024, down 97.7% on a QoQ basis from $21.8 million in Q4 2022.

Exicure (XCUR) Revenue (2016 - 2024) Analysis & Trends

Exicure (XCUR) has 8 years of Revenue data on file, last reported at $500000.0 in Q1 2024.

Quarterly Revenue changed N/A year-over-year to $500000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $500000.0 (changed N/A YoY) and the FY2024 annual result came in at $500000.0, changed N/A from the prior year.
Revenue fell to $500000.0 in Q1 2024, from $21.8 million in the prior quarter.
In the past five years, Revenue ranged from a high of $21.8 million in Q4 2022 to a low of -$2.1 million in Q4 2021.
A 4-year average of $3.7 million and a median of $2.4 million in 2020 frame the typical range for Revenue.
Annual changes were most pronounced in 2020 — Revenue jumped 36632.0% — and 2021, when it sank 1612.86%.
Tracing XCUR's Revenue over 4 years: stood at $140000.0 in 2020, then slumped by 1612.86% to -$2.1 million in 2021, then surged by 1128.05% to $21.8 million in 2022, then sank by 97.7% to $500000.0 in 2024.
The last three Revenue figures came in at $500000.0 (Q1 2024), $21.8 million (Q4 2022), and $2.0 million (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	Exicure	8.41 Mn	8.41 Mn	-	-

Download Data